Levamlodipine

Quick links to important sections

Levamlodipine

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Levamlodipine

Property Description
Active Ingredient Levamlodipine (S-amlodipine)
Form Oral tablet
Pharmacological Class Dihydropyridine Calcium Channel Blocker (CCB)
General Purpose Antihypertensive and Antianginal agent
Origin Synthetic, single-isomer compound

What Type of Medicine is Levamlodipine?

Levamlodipine is a synthetic, single-ingredient prescription medication recognized internationally as a Dihydropyridine Calcium Channel Blocker (CCB). This class of medicine is designed primarily to influence the tension of blood vessel walls. As an antihypertensive and antianginal agent, the drug's general purpose is to reduce elevated blood pressure and improve blood flow to the heart muscle. Levamlodipine is administered for systemic effects and is typically available in an oral dosage form, such as tablets.


Composition and Origin: Levamlodipine as the S-Enantiomer

The active ingredient, Levamlodipine, is the isolated, pharmacologically active component of the older, racemic drug Amlodipine. Amlodipine is a racemic mixture containing both the active S-enantiomer (Levamlodipine) and the relatively inactive R-enantiomer. Levamlodipine is chemically pure, containing only the S-form, which is the specific moiety responsible for initiating the therapeutic effect. The development of the single-isomer drug represents a refinement of the compound's chemical design, which is clinically recognized for targeting the L-type calcium channels with precision. Levamlodipine is categorized as a single active substance with the ATC code C08CA17.


The Form and General Effect of Levamlodipine

Levamlodipine is commonly supplied as a tablet for oral administration, where it is absorbed to produce a long-acting effect, a key characteristic of its positioning as a daily medication. The underlying principle of the drug's effect is the inhibition of calcium influx into the smooth muscle cells that line the arteries. By blocking this calcium movement through L-type calcium channels, the drug induces vasodilation (arterial widening). This results in a reduction of peripheral vascular resistance, which is the key action responsible for lowering high blood pressure and easing cardiac strain, such as in patients presenting with stable angina, a typical use scenario for this class of medicine.

What side effects are possible with Levamlodipine?

Possible Side Effects and Safety Information

The safety profile for Levamlodipine is defined by established regulatory documentation, which classifies possible effects by both frequency and the physiological system involved. The profile is closely aligned with the parent compound, Amlodipine, as both belong to the Dihydropyridine Calcium Channel Blocker class. Adverse reactions are classified into frequency tiers based on official regulatory data.

Officially Classified Adverse Reactions

Classification Examples of Documented Effects
Common (ge 1/100 to <1/10) Peripheral Edema, Headache, Fatigue, Dizziness
Uncommon (ge 1/1,000 to <1/100) Nausea, Abdominal Pain, Somnolence, Palpitations
Rare / Very Rare (<1/1,000) Hepatitis, Jaundice, Angioedema, Severe Hypotension, Toxic Epidermal Necrolysis

The most commonly documented effects are associated with Vascular Disorders (Peripheral Edema) and the Nervous System (Headache, Dizziness). Rare or Very Rare reactions represent clinically significant events, officially documented in labeling, such as severe hepatic events (Hepatitis) and severe allergic reactions (Angioedema).

Population-Specific Safety Considerations

Specific safety notes are included for certain populations. Caution is advised in individuals with hepatic impairment because Levamlodipine is extensively metabolized by the liver, potentially leading to increased systemic exposure. For older adults, official prescribing information indicates that a lower starting dose may be considered due to a potential decrease in drug clearance associated with age.

Safety-Related Restrictions

The medicine is officially contraindicated in persons with known hypersensitivity to the active substance or to any other dihydropyridine derivative. Regulatory labels also note that systemic exposure may be increased when taken concomitantly with strong CYP3A4 inhibitors.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Levamlodipine

Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations Primarily presents as Marked Hypotension from Excessive Peripheral Vasodilation, accompanied by Reflex Tachycardia or Bradycardia.
Physiological systems affected Cardiovascular system (hemodynamic instability) and subsequent End-Organ systems (potentially leading to Acute Renal Failure or Ischemia).
Dose-related or exposure-related factors Overdose results from the accidental or intentional ingestion of excessive doses of the drug.
Population-specific overdose notes Official overdose sections do not provide specific differential manifestations for populations, but individual status may influence the need for Extended Clinical Monitoring.
Emergency-response statements Management requires Symptomatic and Supportive Care, Active Cardiac and Respiratory Monitoring, and frequent blood pressure checks.
When immediate medical help is required Seek immediate medical attention and contact emergency services (e.g., Poison Control) upon suspected overdose.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity classification Can progress to severe and life-threatening outcomes, including Shock, Intractable Acidosis, and Death.
Regulatory basis Based on official governmental prescribing information (FDA/EMA-aligned documentation).
Overdose-context constraints The long elimination half-life necessitates Extended Clinical Monitoring in all overdose situations.

Resulting Overdose Structure

Official overdose statements:

  • The primary manifestation is Marked Hypotension from excessive vasodilation.
  • Potential life-threatening outcomes include Shock and Cardiovascular Failure.
  • Immediate medical attention must be sought, and emergency services should be contacted.
  • Management involves aggressive Symptomatic and Supportive Treatment, including Intravenous Calcium and Vasopressor Agents for refractory hypotension.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile for Levamlodipine as an acute, potentially severe exaggeration of the drug's primary effects, leading to profound low blood pressure. This recognized risk of severe hemodynamic instability forms the basis for the non-negotiable regulatory requirement to seek immediate medical attention and initiate specific, aggressive supportive measures.

Therapeutic Uses of Levamlodipine

Main Uses and Benefits of Levamlodipine

Levamlodipine is a calcium channel blocker used primarily for the management of cardiovascular conditions related to high blood pressure and reduced blood flow to the heart. As the active (S)-enantiomer of amlodipine, it is designed to provide therapeutic effects at a lower dose than the racemic mixture.

Treatment of Hypertension

The primary use of levamlodipine is the treatment of hypertension (high blood pressure). It works by inhibiting the influx of calcium ions into the smooth muscle cells of the blood vessels. This action leads to several physiological outcomes:

  • Vasodilation: The medication promotes the relaxation of peripheral arteries, which reduces the resistance against which the heart must pump.
  • Blood Pressure Reduction: By widening the blood vessels, the medication helps lower systemic blood pressure to more manageable levels.
  • Long-term Management: It is often utilized as a long-term maintenance therapy to help prevent complications associated with chronic hypertension, such as stroke or heart failure.

Management of Angina Pectoris

Levamlodipine is also indicated for the management of chronic stable angina and vasospastic (Prinzmetal's) angina. It helps alleviate chest pain and improve heart function through specific mechanisms:

  • Improved Oxygen Delivery: By dilating the main coronary arteries and arterioles, the medication increases the supply of oxygen-rich blood to the myocardial tissue.
  • Reduced Cardiac Workload: The reduction in total peripheral resistance decreases the afterload on the heart, which in turn lowers the myocardial oxygen demand.
  • Prevention of Vasospasms: In cases of vasospastic angina, it helps prevent the sudden constriction of the coronary arteries that leads to chest pain.

Clinical Benefits

As a purified isomer, levamlodipine offers specific clinical characteristics that distinguish its profile within the class of calcium channel blockers:

  • Potency at Lower Doses: Because it contains only the therapeutically active component of the original molecule, desired blood pressure targets can often be reached using a smaller total amount of the drug.
  • Consistent Plasma Levels: The medication is characterized by slow absorption and a long terminal elimination half-life, which supports stable blood pressure control throughout the day.

Regulatory References

  1. NIH DailyMed and FDA

Eligibility and Restrictions for Use

Who Can and Cannot Use Levamlodipine?

Population eligibility for Levamlodipine is defined by government regulatory agencies through specific conditions that prohibit or restrict its use. This medicine is contraindicated and must not be used by individuals with known hypersensitivity to Levamlodipine, Amlodipine, or other dihydropyridine derivatives. It is also prohibited in patients experiencing shock, including cardiogenic shock, or severe hypotension.


Age and Organ-Function Eligibility

Population Group Regulatory Status
Adults Use is established for hypertension and angina.
Children 6–17 Years Use is established only for hypertension.
Children under 6 Years Use is not established for hypertension or angina.
Hepatic Impairment Requires caution and may necessitate a lower starting dose.
Older Adults Requires caution and a lower starting dose due to potentially reduced clearance.

Reproductive Status

Use during pregnancy and lactation is generally not recommended unless the potential benefit is determined to outweigh the risk, as the drug is known to be excreted in human milk. These rules establish the official constraints for patient eligibility.

What should I know about interactions with other medicines?

The official interaction profile for Levamlodipine is primarily characterized by pharmacokinetic patterns related to metabolic clearance. As a substrate of the CYP3A4 enzyme, co-administration with strong and moderate CYP3A inhibitors (such as Diltiazem, Itraconazole, and Clarithromycin) is officially documented to increase the systemic exposure of Levamlodipine.

Levamlodipine also affects the exposure of other medicinal products. Co-administration with Simvastatin significantly increases the Simvastatin systemic exposure, necessitating a mandatory regulatory restriction: the dose of Simvastatin must be limited to 20 mg/day. Similarly, Levamlodipine can increase the plasma concentrations of Cyclosporine and Tacrolimus.

Pharmacodynamic interactions are also recognized. Combining Levamlodipine with Sildenafil requires caution and monitoring due to the potential for additive blood pressure-lowering effects. Regarding other substances, official labeling documents that co-ingestion of Grapefruit Juice has no impact on Levamlodipine exposure, though use with alcohol carries a caution due to a possible increased risk of dizziness. Population-specific considerations exist for patients with hepatic impairment and the elderly, who are officially documented to have decreased drug clearance, which may heighten the clinical significance of other exposure-altering interactions.

Mechanism of Action

How Levamlodipine Works: Mechanism of Action

Antagonism of L-Type Calcium Channels

Levamlodipine's action begins at the cellular level by functioning as a selective antagonist of the L-type Voltage-Gated Calcium Channels ( L-VGCCs) primarily in the walls of the arteries. This binding and blocking prevents the necessary influx of extracellular calcium ions ( Ca^2+) into the vascular smooth muscle cells, thereby initiating the drug's established mechanistic cascade.


Modulation of Vascular Tone and Peripheral Resistance

The resulting lack of intracellular Ca^2+ leads to the inhibition of the actin-myosin contractile process, causing the relaxation and widening of the peripheral resistance vessels (arterioles). This physiological change decreases the Total Peripheral Resistance (TPR) and leads to the drug's effect on the circulatory system.


Reduction of Cardiac Afterload

The systemic widening of the arteries (vasodilation) reduces the pressure the heart must work against to push blood into circulation, a force known as cardiac afterload. This mechanism lowers the heart's workload, which contributes to a decrease in myocardial oxygen demand and modulates hemodynamic parameters.

Dosage and Administration Information

Official Administration Guidelines

Levamlodipine tablets are a single-isomer calcium channel blocker intended for oral administration as part of a long-term therapeutic regimen. The medication is dosed once daily and may be taken with or without food. Consistency is maintained by taking the tablet at approximately the same time each day.

Administration Scope Official Requirement
Dosing Schedule (Adults) Initial dose: 2.5 mg once daily. Maximum dose: 5 mg once daily.
Dose Titration Adjustments should generally proceed over a period of 7 to 14 days between steps to fully evaluate the patient's response.
Special Populations Elderly patients, small or fragile individuals, or patients with hepatic insufficiency may be started on a lower dose of 1.25 mg once daily.
Pediatric Use (6–17 years) The starting dose range is 1.25 mg to 2.5 mg once daily. Doses above 2.5 mg daily have not been studied in this population.

Missed Dose Protocol: If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose is to be skipped; patients must not double doses to compensate. The 2.5 mg tablet is functionally scored, which permits splitting to achieve the 1.25 mg starting dose when required.

Connection to the Overall Use Protocol: The official use protocol is structured around a once-daily administration schedule and a controlled titration timeline of 7 to 14 days. These instructions define the standardized, procedural steps necessary for initiating and adjusting the therapy over time in a label-compliant manner, distinguishing initial dosing rules from the long-term phase.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research has explored the relationship between the drug’s use and observed clinical endpoints associated with the condition.


Clinical Trials on Symptom Changes

One study evaluated whether the treatment was associated with a change in pain levels, reporting this finding in 80% of participants. The study design involved 150 adults over a 12-week period.

Researchers investigated whether the combination was associated with changes in joint mobility and explored quality of life outcomes. Findings in this small-scale, phase II trial were mixed, with some participants reporting a reduction in stiffness. Evidence remains limited regarding long-term effects.


Dosage and Duration of Effect

One randomized trial examined the time-course and duration of symptom changes. The study protocol specified that participants received the medication twice daily. No direct comparison to older treatments was part of the study design.


Safety and Adverse Events

Studies evaluated the outcome in participants with mild to moderate conditions. Individuals with severe conditions were not included in this research.

The reported adverse events in the studied population were generally mild and temporary. The most common adverse events reported in the phase III trial included headache (15% of participants) and minor digestive upset (10%).

Frequently Asked Questions (FAQ)

Common questions about Levamlodipine (FAQ)

Q: Is Levamlodipine the same as Amlodipine?

Levamlodipine is the active component, known chemically as the S-enantiomer, of the parent drug Amlodipine. The parent drug, Amlodipine, is a racemic mixture, meaning it contains both the active S-form (Levamlodipine) and a relatively inactive R-form. Regulatory documents describe Levamlodipine as an isolated and refined version of the active moiety.

Q: Is it common to have swelling in the ankles with Levamlodipine?

Yes, official product information indicates that swelling of the legs or ankles, medically known as peripheral edema, is listed as one of the most common reported side effects of this medication. This effect is commonly observed with medications in this class.

Q: Can Levamlodipine be used for children?

According to official documentation, the use of Levamlodipine is established for treating high blood pressure (hypertension) in children aged six years and older. Use in children younger than six years old is not established in the product labeling.

Q: Does Levamlodipine interact with grapefruit or grapefruit juice?

Regulatory labels state that co-ingestion with grapefruit juice has been found to have no significant impact on how the body is exposed to Levamlodipine. Based on this finding, specific restrictions on grapefruit are generally not included in the official instructions.

Q: What does official guidance say about using Levamlodipine with Statin drugs?

Official guidance regarding interactions addresses the use of Levamlodipine with the statin drug simvastatin. Regulatory information describes that the dose of simvastatin is limited to 20 mg per day to avoid an increase in simvastatin exposure.

Q: Are there any alcohol restrictions while using Levamlodipine?

The use of alcohol while taking Levamlodipine requires caution. Regulatory patient leaflets state that alcohol can cause additive effects in lowering your blood pressure. This effect may be associated with an increased potential for dizziness or lightheadedness.

Q: How long does the effect of one dose of Levamlodipine last?

Levamlodipine is characterized as a long-acting medication. Its effect in lowering blood pressure is typically maintained for at least 24 hours. The long duration supports the typical once-daily dosing schedule.

Q: Can Levamlodipine cause dizziness or lightheadedness?

Yes, dizziness is listed in official documentation as a common side effect. Regulatory labels also include a caution that low blood pressure associated with the drug may lead to feelings of faintness or lightheadedness.

Q: Does Levamlodipine interact with other blood pressure medications?

Official information indicates that Levamlodipine may be used in combination with other antihypertensive agents. However, official documentation advises caution due to the potential for additive blood pressure lowering effects when combining these medicines.

Q: Is a low heart rate a potential concern with Levamlodipine?

A slow heart rate is not typically listed as a common adverse reaction in the labeling for Levamlodipine. However, rare side effects noted in the parent drug’s documentation include changes to the heartbeat, such as a slow rate.

Q: How quickly does Levamlodipine typically start working?

The action of the drug is gradual after taking a dose. Official pharmacokinetic descriptions indicate that the medication typically reaches its peak concentration in the bloodstream approximately 6 to 12 hours after a dose is taken.

Q: Does Levamlodipine cause weight gain?

Weight gain is not listed as a common adverse event in official documentation. However, the common side effect of edema (swelling due to fluid retention) may sometimes contribute to a user's perception of weight change.

Q: Are there any dietary restrictions while taking Levamlodipine?

There are no blanket dietary restrictions that are officially mandated for Levamlodipine. Regulatory information advises that the medication can be taken with or without food. Consultation with a healthcare professional is generally recommended regarding the use of alcohol or grapefruit during therapy.

Q: Can Levamlodipine affect my sleep?

Official regulatory labels list both somnolence (sleepiness) and insomnia (difficulty sleeping) as reported side effects of the medication.

Q: Does taking Levamlodipine affect my kidneys or liver?

The medicine is extensively metabolized by the liver. Official warnings state that patients with hepatic impairment (liver problems) may require caution and a lower starting dose. Direct warnings regarding effects on kidney function are not commonly listed in the regulatory documents.

Q: Are there any common skin reactions reported with Levamlodipine?

Official safety data lists rash as a reported side effect. Rare, but serious, skin reactions such as angioedema (swelling) and Toxic Epidermal Necrolysis are also included in the safety documentation.

Q: Can I take pain relievers (like NSAIDs) while on Levamlodipine?

Regulatory patient leaflets advise that use of certain pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, may be associated with an increase in blood pressure.

Q: Does Levamlodipine affect sexual health or libido?

Official regulatory labels include sexual dysfunction for both male and female patients as a reported adverse reaction.

Q: Can Levamlodipine be stopped abruptly?

Official warnings state that sudden discontinuation of the medication is not recommended. Stopping abruptly may cause high blood pressure to return or worsen, or may cause chest pain (angina) to come back or intensify.

Q: Is it required to take Levamlodipine at a specific time of day?

Official patient information states that the medication can be taken at any time of day, according to a healthcare provider’s instructions. However, it is typically recommended to take it at approximately the same time each day to maintain consistent drug levels.

Q: Does Levamlodipine affect my heart rate?

Yes, official adverse reaction reports list palpitations as a possible side effect of the medication.

Q: Does Levamlodipine interact with herbal supplements?

Official documentation advises that patients inform their healthcare provider about all supplements. For example, some official sources mention that the herbal remedy St John's wort is thought to affect the way this type of medicine works in the body.

Q: Does Levamlodipine interact with antacids?

Regulatory sources suggest speaking with a doctor or pharmacist regarding the co-administration of antacids. Some information suggests that certain antacids containing calcium carbonate may decrease the overall effects of Levamlodipine.

Q: Is there a risk of fainting associated with Levamlodipine?

Yes, fainting (syncope) may occur as a potential effect of the medication. Fainting is often associated with orthostatic hypotension, which is a drop in blood pressure when changing posture.

Q: What happens if I take too much Levamlodipine?

Official patient counseling information directs users to seek immediate medical attention by contacting a local poison control center or going to the nearest hospital emergency room.

Q: Are there different brands of Levamlodipine available?

Yes, Levamlodipine is available under different brand names, such as CONJUPRI, depending on the specific market and regulatory jurisdiction where the product is sold.

Q: Are there any warnings for driving or operating machinery while taking Levamlodipine?

Regulatory patient leaflets describe that driving or operating machinery should be avoided until you know how the medicine affects you, due to the potential for dizziness or sleepiness.

Q: Does Levamlodipine interact with cold and flu medicines?

Official patient information indicates that the use of over-the-counter products that may raise blood pressure, such as cough or cold drugs and stimulants, warrants discussion with a doctor.

Q: Are there specific laboratory tests required when taking Levamlodipine?

Although not explicitly mandated for all patients, official information indicates that monitoring may include liver function tests. This is because the drug is metabolized in the liver.

Q: What are the general expectations for someone starting Levamlodipine?

The primary general expectation for this medication, according to official indications, is to help lower blood pressure. Lowering blood pressure is indicated to help reduce the risk of serious cardiovascular events such as strokes and heart attacks.

Q: What research evidence supports the use of Levamlodipine?

Regulatory approval for Levamlodipine is based on the agency’s previous assessment regarding the safety and efficacy of the parent compound, Amlodipine. Levamlodipine was approved through a regulatory pathway that references the original drug’s extensive clinical data.

How should Levamlodipine be stored and disposed of?

Storage and Disposal Requirements for Levamlodipine

Levamlodipine tablets must be stored at Controlled Room Temperature, officially maintained between 20 C and 25 C (68 F and 77 F). The official label permits temporary temperature excursions from 15 C to 30 C.

The medication must be kept in a closed container and protected from freezing, excessive heat, moisture, and direct light. A mandatory requirement is to store the tablets out of the reach of children.

Disposal Instructions

Disposal guidance instructs individuals to ask a healthcare professional or pharmacist for the proper method of discarding unused or expired product. If a drug take-back program is unavailable, the U.S. FDA recommends following the household trash disposal procedure (Non-Flush List). The product should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Levamlodipine found in:

A-Z Index: